Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA. Shares in the company gained almost 24% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback